Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

NCT05882630 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

39

Enrollment

OTHER_GOV

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Surufatinib,Serplulimab,Etoposide,Carboplatin

Sponsor

Fujian Cancer Hospital

Collaborators

[object Object]
[object Object]